- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| OMEGA THERAPEUTICS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 70,40 | 0,00 % | CG Oncology-Aktie erreicht Rekordhoch von 72,29 US-Dollar | ||
| KYMERA THERAPEUTICS | 86,93 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma | KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track... ► Artikel lesen | |
| DISC MEDICINE | 71,41 | 0,00 % | Disc Medicine Inc: Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria | Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP)The study size was expanded to 183 participants due to patient and physician... ► Artikel lesen | |
| VERA THERAPEUTICS | 41,610 | 0,00 % | Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 16,580 | 0,00 % | Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting | ||
| ERASCA | 21,700 | 0,00 % | Jefferies reiterates Erasca stock Buy rating ahead of ASCO data | ||
| ENVERIC BIOSCIENCES | 3,575 | 0,00 % | Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On? | ||
| PSYENCE BIOMEDICAL | 11,210 | 0,00 % | Psyence Biomedical Ltd.: Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine | NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 46,410 | -3,44 % | Enliven Therapeutics (ELVN) Up 194% This Year on Strong CML Market | ||
| HARMONY BIOSCIENCES | 29,530 | 0,00 % | Dravet-Syndrom: Harmony Biosciences präsentiert neue Studiendaten | ||
| ARRIVENT BIOPHARMA | 31,390 | 0,00 % | ArriVent BioPharma, Inc.: ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer | Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to support... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 25,120 | 0,00 % | UBS reiterates Buy on Summit Therapeutics stock ahead of trial data | ||
| ARCELLX | 115,01 | 0,00 % | Gilead Sciences, Inc. Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer | FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx... ► Artikel lesen | |
| BICARA THERAPEUTICS | 23,470 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 Announced development of a less frequent loading... ► Artikel lesen | |
| CLIMB BIO | 8,970 | -1,86 % | Mizuho nimmt Coverage für Climb Bio-Aktie mit "Outperform"-Rating auf |
OMEGA THERAPEUTICS INC gehört der Branche Biotechnologie an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OMEGA THERAPEUTICS INC finden Sie auf Wallstreet Online.